Chong Kun Dang Pharmaceutical Balance Sheet Health
Financial Health criteria checks 6/6
Chong Kun Dang Pharmaceutical has a total shareholder equity of ₩895.6B and total debt of ₩208.7B, which brings its debt-to-equity ratio to 23.3%. Its total assets and total liabilities are ₩1,461.5B and ₩565.9B respectively. Chong Kun Dang Pharmaceutical's EBIT is ₩207.1B making its interest coverage ratio -62.8. It has cash and short-term investments of ₩334.3B.
Key information
23.3%
Debt to equity ratio
₩208.75b
Debt
Interest coverage ratio | -62.8x |
Cash | ₩334.27b |
Equity | ₩895.59b |
Total liabilities | ₩565.90b |
Total assets | ₩1.46t |
Recent financial health updates
Is Chong Kun Dang Pharmaceutical (KRX:185750) Using Too Much Debt?
Oct 24Chong Kun Dang Pharmaceutical (KRX:185750) Seems To Use Debt Rather Sparingly
May 27Does Chong Kun Dang Pharmaceutical (KRX:185750) Have A Healthy Balance Sheet?
Apr 19Does Chong Kun Dang Pharmaceutical (KRX:185750) Have A Healthy Balance Sheet?
Jan 12Recent updates
Is Chong Kun Dang Pharmaceutical (KRX:185750) Using Too Much Debt?
Oct 24Investors Aren't Buying Chong Kun Dang Pharmaceutical Corp.'s (KRX:185750) Earnings
Sep 27Does Chong Kun Dang Pharmaceutical (KRX:185750) Deserve A Spot On Your Watchlist?
Sep 08Are Investors Undervaluing Chong Kun Dang Pharmaceutical Corp. (KRX:185750) By 41%?
Jul 30Investors Don't See Light At End Of Chong Kun Dang Pharmaceutical Corp.'s (KRX:185750) Tunnel
Jun 12Chong Kun Dang Pharmaceutical (KRX:185750) Seems To Use Debt Rather Sparingly
May 27A Look At The Fair Value Of Chong Kun Dang Pharmaceutical Corp. (KRX:185750)
Apr 09Does Chong Kun Dang Pharmaceutical (KRX:185750) Have A Healthy Balance Sheet?
Apr 19Here's Why I Think Chong Kun Dang Pharmaceutical (KRX:185750) Is An Interesting Stock
Apr 05Declining Stock and Solid Fundamentals: Is The Market Wrong About Chong Kun Dang Pharmaceutical Corp. (KRX:185750)?
Mar 09Estimating The Fair Value Of Chong Kun Dang Pharmaceutical Corp. (KRX:185750)
Feb 24The Chong Kun Dang Pharmaceutical (KRX:185750) Share Price Is Up 112% And Shareholders Are Boasting About It
Feb 11Is Chong Kun Dang Pharmaceutical Corp. (KRX:185750) An Attractive Dividend Stock?
Jan 27Does Chong Kun Dang Pharmaceutical (KRX:185750) Have A Healthy Balance Sheet?
Jan 12With EPS Growth And More, Chong Kun Dang Pharmaceutical (KRX:185750) Is Interesting
Dec 28What Kind Of Shareholders Hold The Majority In Chong Kun Dang Pharmaceutical Corp.'s (KRX:185750) Shares?
Dec 09Could The Market Be Wrong About Chong Kun Dang Pharmaceutical Corp. (KRX:185750) Given Its Attractive Financial Prospects?
Nov 24Financial Position Analysis
Short Term Liabilities: A185750's short term assets (₩984.0B) exceed its short term liabilities (₩387.3B).
Long Term Liabilities: A185750's short term assets (₩984.0B) exceed its long term liabilities (₩178.6B).
Debt to Equity History and Analysis
Debt Level: A185750 has more cash than its total debt.
Reducing Debt: A185750's debt to equity ratio has reduced from 24% to 23.3% over the past 5 years.
Debt Coverage: A185750's debt is well covered by operating cash flow (88.7%).
Interest Coverage: A185750 earns more interest than it pays, so coverage of interest payments is not a concern.
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2024/12/24 18:09 |
End of Day Share Price | 2024/12/24 00:00 |
Earnings | 2024/09/30 |
Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Chong Kun Dang Pharmaceutical Corp. is covered by 21 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Hyerin Lee | DAOL Investment & Securities Co., Ltd. |
Jisoo Lee | DAOL Investment & Securities Co., Ltd. |
null null | DBS Bank Ltd |